Trials / Completed
CompletedNCT01815242
Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer - Triple Negative Breast Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 336 (estimated)
- Sponsor
- West German Study Group · Academic / Other
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The trial will evaluate the optimal treatment with nab-paclitaxel in combination with either carboplatin or gemcitabine for patients with triple negative breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | nab-Paclitaxel | |
| DRUG | Gemcitabine | |
| DRUG | Carboplatin |
Timeline
- Start date
- 2013-06-01
- Primary completion
- 2015-03-01
- Completion
- 2025-01-15
- First posted
- 2013-03-21
- Last updated
- 2025-02-27
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT01815242. Inclusion in this directory is not an endorsement.